Literature DB >> 11152330

Triple marker screening for trisomy 21, trisomy 18 and open neural tube defects in singleton pregnancies of native Japanese pregnant women.

T Onda1, T Tanaka, K Yoshida, Y Nakamura, R Kudo, H Yamamoto, A Sato, K Yanagida, Y Takai, H Uemura, K Hoshi, Y Fukada, Y Miyake, M Ohnishi, T Kaneoka, Y Makino, Y Murata, T Kanzaki, H Kanzaki, T Osaki, T Aono, K Maeda, S Ogita, S Yamamasu, T Aso, Y Shimizu, T Izutsu, T Kudo, T Okai, M Sakai, T Hashimoto, N Matsuzaki, M Kitagawa, H Sago, R E Grier, F Myrick, Y Shimizu.   

Abstract

OBJECTIVE: To report the results of prenatal triple marker screening on a population of Japanese pregnant women.
METHODS: From April 1994 through March 1999, a total of 32,925 native Japanese women with singleton pregnancies requested a triple marker-screening test. Multiples of the median values for 3 markers and individual risks for each patient were calculated following adjustment for the Japanese weight correction factor. The risk cut-off values used for Down syndrome (T21), open spina bifida (OSB) and trisomy 18 (T18) were 1: 295, 1: 290, and 1: 100, respectively. Follow-up information was collected postpartum and statistically analyzed.
RESULTS: Detection rates (DR) of T21 for women less than 35 years, over 35 years and overall were 58, 94, and 83%, respectively. DR of T18 for women less than 35 years, over 35 years and overall were 75, 79, and 79%, respectively. DR of open neural tube defects (ONTD) was 100%.
CONCLUSIONS: The first cumulative data of an intervention program and prospective follow-up studies in Japan have proven to be similar to other published reports. Individual risk values were calculated for each pregnancy for T21, T18 and ONTD. This screening program is more effective than age-dependent screening for detecting T21, T18 and ONTD pregnancies.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11152330     DOI: 10.1111/j.1447-0756.2000.tb01355.x

Source DB:  PubMed          Journal:  J Obstet Gynaecol Res        ISSN: 1341-8076            Impact factor:   1.730


  7 in total

Review 1.  First trimester ultrasound tests alone or in combination with first trimester serum tests for Down's syndrome screening.

Authors:  S Kate Alldred; Yemisi Takwoingi; Boliang Guo; Mary Pennant; Jonathan J Deeks; James P Neilson; Zarko Alfirevic
Journal:  Cochrane Database Syst Rev       Date:  2017-03-15

Review 2.  First and second trimester serum tests with and without first trimester ultrasound tests for Down's syndrome screening.

Authors:  S Kate Alldred; Yemisi Takwoingi; Boliang Guo; Mary Pennant; Jonathan J Deeks; James P Neilson; Zarko Alfirevic
Journal:  Cochrane Database Syst Rev       Date:  2017-03-15

Review 3.  Second trimester serum tests for Down's Syndrome screening.

Authors:  S Kate Alldred; Jonathan J Deeks; Boliang Guo; James P Neilson; Zarko Alfirevic
Journal:  Cochrane Database Syst Rev       Date:  2012-06-13

4.  Study on amniotic fluid metabolism in the second trimester of Trisomy 21.

Authors:  Xiaoting Liu; Sheng Quan; Yurong Fu; Weiwei Wang; Wenling Zhang; Xiaofei Wang; Chenxi Zhang; Daijun Xiang; Liwen Zhang; Chengbin Wang
Journal:  J Clin Lab Anal       Date:  2019-11-10       Impact factor: 2.352

Review 5.  First trimester serum tests for Down's syndrome screening.

Authors:  S Kate Alldred; Yemisi Takwoingi; Boliang Guo; Mary Pennant; Jonathan J Deeks; James P Neilson; Zarko Alfirevic
Journal:  Cochrane Database Syst Rev       Date:  2015-11-30

Review 6.  Urine tests for Down's syndrome screening.

Authors:  S Kate Alldred; Boliang Guo; Yemisi Takwoingi; Mary Pennant; Susanna Wisniewski; Jonathan J Deeks; James P Neilson; Zarko Alfirevic
Journal:  Cochrane Database Syst Rev       Date:  2015-12-10

Review 7.  Beyond Trisomy 21: Additional Chromosomal Anomalies Detected through Routine Aneuploidy Screening.

Authors:  Amy Metcalfe; Catriona Hippman; Melanie Pastuck; Jo-Ann Johnson
Journal:  J Clin Med       Date:  2014-04-08       Impact factor: 4.241

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.